

**Discussions with leaders:** *JNM* editor-in-chief Johannes Czernin talks with Howard Soule, of the Prostate Cancer Foundation, about supporting and encouraging research in an environment of rapidly changing scientific knowledge and clinical practice. . . . **Page 774**

**Leading in a time of pandemic:** Johnese Spisso, president of UCLA Health and CEO of the UCLA Hospital System, discusses with *JNM* editor-in-chief Johannes Czernin challenges and strategies in managing health-care delivery during the COVID-19 outbreak. . . . **Page 777**

**Bombesin imaging in cancer:** Baratto and colleagues offer a state-of-the-art overview of the bombesin receptor family, with a focus on gastrin-releasing peptide receptors and on applications in prostate and breast cancers. . . . **Page 792**

**Molecular imaging of bone metastases:** Cook and Goh provide an educational review of the role of new molecular and hybrid methods, including SPECT/CT, PET/CT, and whole-body MR, for imaging bone metastases. . . . **Page 799**

**Aromatase imaging in breast cancer:** Biegon and colleagues validate and optimize PET imaging with  $^{11}\text{C}$ -vorozole for in vivo measurement of aromatase expression in individual breast cancer lesions in postmenopausal women. . . . **Page 807**

**PET/CT radiomics in lung cancer SBRT:** Dissaux and colleagues develop and evaluate a prognostic  $^{18}\text{F}$ -FDG PET/CT radiomic signature in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy. . . . **Page 814**

**$^{18}\text{F}$ -FDG PET/CT and hyperprogressive cancer:** Castello and colleagues use  $^{18}\text{F}$ -FDG PET/CT to investigate the prevalence of hyperprogressive disease as a pattern of response during treatment of non-small cell lung cancer with immune checkpoint inhibitors. . . . **Page 821**

**$^{11}\text{C}$ -Choline PET/CT in recurrent prostate cancer:** Michaud and colleagues report on the performance of  $^{11}\text{C}$ -choline

PET/CT in detecting biochemically recurrent prostate cancer in a large non-European cohort and describe patterns of recurrence. . . . **Page 827**

**Integrated roadmap for fluorescence guidance:** Meershoek and colleagues detail the role of positional data from SPECT/CT in providing a 3D preoperative imaging roadmap for fluorescence-guided surgery in prostate cancer. . . . **Page 834**

**Co-clinical imaging:** Savaikar and colleagues develop and optimize image metrics for  $^{18}\text{F}$ -FDG PET to assess response to combination docetaxel and carboplatin therapy in a co-clinical trial involving triple-negative breast cancer patient-derived xenografts. . . . **Page 842**

**PARP-1-targeted Auger therapy:** Lee and colleagues assess the cytotoxicity of chromatin-targeted Auger therapy in pre-clinical models of high-risk neuroblastoma and discuss the potential for use in micrometastatic disease. . . . **Page 850**

**$^{177}\text{Lu}$ -PSMA-617 in prostate cancer:** Violet and colleagues report longer-term outcomes in an expanded cohort from a trial of this prostate-specific membrane-targeting radioligand in men with metastatic castration-resistant prostate cancer. . . . **Page 857**

**3-Year freedom from progression in BCR:** Emmett and colleagues describe the predictive value of  $^{68}\text{Ga}$ -prostate-specific membrane antigen PET for 3-y freedom from progression in men with biochemical recurrence of prostate cancer undergoing salvage radiotherapy. . . . **Page 866**

**$^{68}\text{Ga}$ -PSMA PET/CT and PTEN-loss PCa:** Wang and colleagues explore the value of  $^{68}\text{Ga}$ -prostate-specific membrane antigen PET/CT for detection of phosphatase and tensin homolog-loss prostate cancer. . . . **Page 873**

**$^{18}\text{F}$ -DCFPyL PET/CT in prostate cancer:** Mena and colleagues investigate the lesion detection rate of this prostate-specific membrane antigen-targeted PET agent in patients with biochemically re-

lapsed prostate cancer after primary local therapy. . . . **Page 881**

**$^{64}\text{Cu}$ -DOTATATE in NETs:** Delpassand and colleagues prospectively determine the lowest optimal dose of this tracer and evaluate its diagnostic performance and safety in a phase III study of patients with somatostatin receptor-expressing neuroendocrine tumors. . . . **Page 890**

**$^{68}\text{Ga}$ -DOTA-JR11 in NETs:** Zhu and colleagues compare PET/CT results with this somatostatin receptor subtype 2-specific antagonist with those from  $^{68}\text{Ga}$ -DOTATATE in patients with metastatic, well-differentiated neuroendocrine tumors. . . . **Page 897**

**Glucose transport in neuroendocrine prostate cancer:** Bakht and colleagues evaluate the association between neuroendocrine gene signature and  $^{18}\text{F}$ -FDG uptake-associated genes in prostate cancer, including glucose transporters and hexokinases. . . . **Page 904**

**$^{18}\text{F}$ -PI-2620 tau PET in humans:** Mueller and colleagues assess the ability of imaging with this PET tracer to detect tau pathology in patients with Alzheimer disease and report on associated safety and tolerability. . . . **Page 911**

**$^{18}\text{F}$ -PI-2620 kinetics and quantification:** Bullich and colleagues detail the biodistribution, dosimetry, quantitative methods, and test-retest variability of this next-generation tau PET tracer in the human brain. . . . **Page 920**

**Brain nicotine uptake and E-cigarettes:** Solingapuram Sai and colleagues use  $^{11}\text{C}$ -nicotine PET to describe brain nicotine uptake and kinetics after inhalation from electronic cigarettes and compare these with results from smoking combustible cigarettes. . . . **Page 928**

**Accuracy of 2-FDG determinations:** Barrio and colleagues look at potential limitations of assuming 2-FDG as a surrogate for glucose metabolic rate and potential reasons for variability in the lump constant. . . . **Page 931**